FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, namely to a composition containing a concentrated therapeutic phospholipid extract for the treatment of cardiovascular diseases, where the extract includes phospholipid compounds of the Formula I: $$$ (I); where R1 and R2 each independently is a residue of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA); each X is independently selected from -CH2CH2NH3, -CH2CH2N(CH3)3 or $$$ ; the total amount of phospholipids in the composition is in a concentration of 50% by weight of phospholipids per the total weight of the composition to 99% by weight of phospholipids per the total weight of the composition, where the composition additionally contains free EPA and free DHA; where the total amount of EPA in the composition is from 15 wt.% up to 25 wt.%; and the total amount of DHA in the composition is from 10 wt.% to 15 wt.%, and also relates to a capsule for the treatment of cardiovascular diseases containing a concentrated therapeutic extract of krill oil, where the concentrated therapeutic extract of krill oil contains phospholipid compounds of the Formula I: $$$ (I); where R1 and R2 each independently is a residue of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA); each X is independently selected from -CH2CH2NH3, -CH2CH2N(CH3)3 or $$$ ; the total amount of phospholipids in the extract is in a concentration from 50% by weight of phospholipids from the total weight of the composition to 99% by weight of phospholipids from the total weight of the composition; and the composition additionally contains free EPA and free DHA; where the total amount of EPA in the composition is from 15 wt.% to 25 wt.%; and the total amount of DHA in the composition is from 10 wt.% to 15 wt.%, the extract is suitable for human consumption, and also relates to the use of the composition for the production of pharmaceutical compositions to reduce the level of triglycerides in blood serum.
EFFECT: group of inventions provides a reduction in the level of triglycerides in plasma.
26 cl, 2 tbl, 35 dwg, 7 ex
